Bahrani Saeide, Sadeghi Masoumeh, Teimouri-Jervekani Zahra, Nouri Fatemeh, Sarrafzadegan Nizal
Student Research Committee, Isfahan University of Medical Sciences, Isfahan, Iran.
Hypertension Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran.
Int J Prev Med. 2023 May 24;14:56. doi: 10.4103/ijpvm.ijpvm_211_21. eCollection 2023.
Due to lack of contemporary data on the presentation, management, and mortality of acute coronary syndrome (ACS) admissions in Iran, in this prospective registry study, we aimed to evaluate the presentation, management, and mortality as the outcome of patients with ACS in Isfahan, Iran, 2001-2016 to address treatment and healthcare depletions.
Data of 62,276 patients admitted with the diagnosis of ACS from 2001 to 2016 prospectively were obtained by Surveillance Unit of Isfahan Cardiovascular Research Center, Isfahan, Iran, in 13 hospitals of Isfahan province. We evaluated data on presentation, management, and in-hospital and 28-day mortality.
Nearly half of the patients ranged in age from 51 to 70 years (32050, 51.5%), which did not differ among ACS types (ST-segment myocardial infarction (STEMI): 53.9%; non-STEMI: 53.4%; unstable angina: 51.9%). In-hospital, anti-platelets use was high (84.9%). Thrombolytic were used in 48.1% of STEMI, 3.8% of non-STEMI, and 1.1% of unstable angina. Discharge medication rates were suboptimal. In-hospital and 28-day mortality were highest for STEMI (6.5 and 12.6%, respectively).
These data represent the large ACS registry in Iran. Data revealed the various presentations of ACS and demonstrated opportunities for improving ACS management by focusing on increasing use of recommended drugs especially after discharge due to suboptimal medical treatment in these patients. The high mortality rate needs to be taken into consideration in ACS patients.
由于缺乏关于伊朗急性冠状动脉综合征(ACS)入院患者的临床表现、治疗及死亡率的当代数据,在这项前瞻性登记研究中,我们旨在评估2001 - 2016年伊朗伊斯法罕ACS患者的临床表现、治疗及死亡率,以解决治疗和医疗保健方面的不足。
2001年至2016年期间,伊朗伊斯法罕心血管研究中心监测部门在伊斯法罕省的13家医院前瞻性收集了62276例诊断为ACS患者的数据。我们评估了临床表现、治疗以及住院期间和28天死亡率的数据。
近一半患者年龄在51至70岁之间(32050例,51.5%),在不同类型的ACS中无差异(ST段抬高型心肌梗死(STEMI):53.9%;非STEMI:53.4%;不稳定型心绞痛:51.9%)。住院期间,抗血小板药物使用率较高(84.9%)。48.1%的STEMI患者、3.8%的非STEMI患者和1.1%的不稳定型心绞痛患者使用了溶栓药物。出院用药率不理想。STEMI患者的住院死亡率和28天死亡率最高(分别为6.5%和12.6%)。
这些数据代表了伊朗大型的ACS登记研究。数据揭示了ACS的各种临床表现,并表明通过关注增加推荐药物的使用,特别是在这些患者出院后因治疗不理想的情况下,有机会改善ACS的管理。ACS患者的高死亡率需要引起重视。